Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00704665
Recruitment Status : Completed
First Posted : June 25, 2008
Last Update Posted : June 25, 2008
University of California, Los Angeles
Boston University
University of Chicago
UConn Health
Johns Hopkins University
University of Pittsburgh
Medical University of South Carolina
Stanford University
Georgetown University
University of California, San Diego
Wayne State University
University of Colorado, Denver
Medical College of Wisconsin
Information provided by:
Rutgers, The State University of New Jersey

Brief Summary:
Relaxin is a naturally occurring protein prduced by the ovary or placenta in pregnancy. It has ani-fibrotic properties. Previous studies have shown that relaxin is safe at concentrations upto 60 times higher than achieved in pregnancy. Study is designed to see if skin improvement and improvement in functional ability can be achieved.

Condition or disease Intervention/treatment Phase
Systemic Sclerosis Drug: Relaxin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 231 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Relaxin in the Treatment of Systemic Sclerosis With Diffuse Scleroderma
Study Start Date : December 1998
Actual Primary Completion Date : December 2001
Actual Study Completion Date : December 2001

Arm Intervention/treatment
Placebo Comparator: 2
Drug: Relaxin

Experimental: A
10ug/kg/day or 25/ug/kg/day
Drug: Relaxin
10 ug/kg/day or 25 ug/kg/day

Primary Outcome Measures :
  1. MRSS [ Time Frame: baseline, weeks 4,12, and 24 ]

Secondary Outcome Measures :
  1. HAQ-DI [ Time Frame: baseline, weeks 4, 12, and 24 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women 18 to 70 years of age with diffuse SSc
  • Disease duration 5 years since the onset of the first non-Raynaud sign or symptom
  • A baseline modified Rodnan skin score (MRSS) of 20 or greater, or at least 16 if truncal involvement was present.
  • Recombinant human relaxin (10 or 25 ug/kg/day), or placebo was administered for 24 weeks as a continuous subcutaneous infusion and there was a follow-up safety visit at week 28.

Layout table for additonal information
Responsible Party: James R. Seibold, UMDNJ Identifier: NCT00704665    
Other Study ID Numbers: 2773
First Posted: June 25, 2008    Key Record Dates
Last Update Posted: June 25, 2008
Last Verified: June 2008
Keywords provided by Rutgers, The State University of New Jersey:
Diffuse Scleroderma
Skin score
Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Systemic
Scleroderma, Diffuse
Pathologic Processes
Connective Tissue Diseases
Skin Diseases
Muscle Relaxants, Central
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents